By Jeff Montgomery ( June 19, 2017, 8:55 PM EDT) -- Attorneys for a Calistoga Pharmaceuticals Inc. stockholder agent told Delaware's Supreme Court Monday that the state chancellor incorrectly qualified the terms for a $50 million drug-approval bonus earlier this year, letting merger partner Gilead Sciences off the hook for the payment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.